CASE REPORT
Challenges in diagnosing ovarian sertoli-leydig cell tumors: A Peruvian case series
More details
Hide details
1
Division of Endocrinology, Hospital Nacional Guillermo Almenara Irigoyen, Lima, PERU
2
Universidad Científica del Sur, Lima, PERU
3
Division of Endocrinology, Clínica Jesús del Norte, Lima, PERU
4
Division of Non-Communicable Diseases, Hospital de Apoyo Chepén, Chepén, PERU
5
Division of Anatomic Pathology, Hospital Nacional Guillermo Almenara Irigoyen, Lima, PERU
Publication date: 2024-09-10
Electron J Gen Med 2024;21(5):em605
KEYWORDS
ABSTRACT
Introduction:
The virilizing ovarian tumors represent less than 1% of ovarian tumors, with the most common being Sertoli-Leydig cell tumor (SLCT). This stufy is a case series.
Methods:
We present the diagnosis, treatment, and evolution of 2 Peruvian women who developed virilization.
Results:
Case 1 is a 27-year-old woman with a history of polycystic ovary syndrome (PCOS), whose usual treatment was combined oral contraceptives, which she discontinued in the last year; she presented with voice changes,
increased muscular strength, and acne of 6 months duration. Physical examination revealed only clitoromegaly.
Tests showed elevated total testosterone, normal dehydroepiandrosterone sulfate (DHEA-S), and transvaginal
ultrasound with isoechoic image in frosted glass in the left ovary. Left salpingo-oophorectomy was performed,
revealing SLCT. Case 2 is a 48-year-old woman with a history of PCOS since the age of 25, prediabetes, and
dyslipidemia; she noticed progression of hirsutism, increased libido, deepened voice, alopecia, weight gain, and
amenorrhea over the last 5 years. Physical examination revealed hirsutism, alopecia, and clitoromegaly. Tests
showed markedly elevated total testosterone (1,080 ng/dl) and normal DHEA-S. Transvaginal ultrasound showed
a larger right ovary, without tumor. Ovarian venous sampling showed lateralization towards the right ovary.
Bilateral salpingo-oophorectomy plus hysterectomy was performed, revealing SLCT in the right ovary. In both
post-surgery patients, there was normalization of androgens and clinical improvement.
Conclusions:
SLCT s can occur at any age, with rapidly evolving hyperandrogenism and/or virilization symptoms,
the cases described were of unusual presentation, which posed a diagnostic challenge.
REFERENCES (16)
1.
Cussen L, McDonnell T, Bennett G, Thompson CJ, Sherlock M, O’reilly MW. Approach to androgen excess in women: Clinical and biochemical insights. Clin Endocrinol (Oxf). 2022;97(2):174-86.
https://doi.org/10.1111/cen.14... PMid:35349173 PMCid:PMC9541126.
2.
Rojewska P, Meczekalski B, Bala G, Luisi S, Podfigurna A. From diagnosis to treatment of androgen-secreting ovarian tumors: A practical approach. Gynecol Endocrinol. 2022;38(7):537-42.
https://doi.org/10.1080/095135... PMid:35647677.
3.
Nef J, Huber DE. Ovarian Sertoli-Leydig cell tumours: A systematic review of relapsed cases. Eur J Obstet Gynecol Reprod Biol. 2021;263:261-74.
https://doi.org/10.1016/j.ejog... PMid:34245994.
4.
Macut D, Ilić D, Mitrović Jovanović A, Bjekić-Macut J. Androgen-Secreting ovarian tumors. Front Horm Res. 2019;53:100-7.
https://doi.org/10.1159/000494... PMid:31499493.
5.
Zou M, Chen R, Wang Y, et al. Clinical and ultrasound characteristics of virilizing ovarian tumors in pre- and postmenopausal patients: A single tertiary center experience. Orphanet J Rare Dis. 2021;16(1):426.
https://doi.org/10.1186/s13023... PMid:34641931 PMCid:PMC8513290.
6.
Horta M, Cunha TM. Sex cord-stromal tumors of the ovary: A comprehensive review and update for radiologists. Diagn Interv Radiol. 2015;21(4):277-86.
https://doi.org/10.5152/dir.20... PMid:26054417 PMCid:PMC4498422.
7.
Hirschberg AL. Approach to investigation of hyperandrogenism in a postmenopausal woman. J Clin Endocrinol Metab. 2023;108(5):1243-53.
https://doi.org/10.1210/clinem... PMid:36409990 PMCid:PMC10099172.
8.
Sharma A, Welt CK. Practical approach to hyperandrogenism in women. Med Clin North Am. 2021;105(6):1099-116.
https://doi.org/10.1016/j.mcna... PMid:34688417 PMCid:PMC8548673.
9.
Elhassan YS, Idkowiak J, Smith K, et al. Causes, patterns, and severity of androgen excess in 1205 consecutively recruited women. J Clin Endocrinol Metab. 2018; 103(3):1214-23.
https://doi.org/10.1210/jc.201... PMid:29342266 PMCid:PMC5868408.
10.
Tjitro A, Wong DA, Ajmal A, Buddhdev K, Brady R. Virilization by an ovarian tumor: Presentation is not always acute. J Investig Med High Impact Case Rep. 2022;10:23247096211056494.
https://doi.org/10.1177/232470... PMid:35596563 PMCid:PMC9127196.
11.
Fleckenstein G, Sattler B, Hinney B, Wuttke W, Osmers R, Emons G. Androblastoma of the ovary: Clinical, diagnostic and histopathologic features. Onkologie. 2001;24(3):286-91.
https://doi.org/10.1159/000055... PMid:11455224.
12.
Wiebe RH, Morris CV. Testosterone/androstenedione ratio in the evaluation of women with ovarian androgen excess. Obstet Gynecol. 1983;61(3):279-84.
13.
Yance VRV, Marcondes JAM, Rocha MP, et al. Discriminating between virilizing ovary tumors and ovary hyperthecosis in postmenopausal women: Clinical data, hormonal profiles and image studies. Eur J Endocrinol. 2017;177(1):93-102.
https://doi.org/10.1530/EJE-17... PMid:28432270.
14.
Yang N, Cao D, Yang J, You Y, Shen K. Prognosis and related factors of preserved fertility function for ovarian sertoli-leydig cell tumor. J Shandong Univ (Health Sci). 2018;56(5):30-4.
15.
Gui T, Cao D, Shen K, et al. A clinicopathological analysis of 40 cases of ovarian Sertoli-Leydig cell tumors. Gynecol Oncol. 2012;127(2):384-9.
https://doi.org/10.1016/j.ygyn... PMid:22850410.
16.
Kandukuri SR, Rao J. FIGO 2013 staging system for ovarian cancer: What is new in comparison to the 1988 staging system? Curr OpinObstet Gynecol. 2015;27(1):48-52.
https://doi.org/10.1097/GCO.00... PMid:25490382.